The overview: about $95 to $110 billion of outside spending
[Chart: Grand View Research, Global Market Insights, Precedence Research, IMARC, ResearchAndMarkets, Straits, Coherent (2025-2026 releases). See the live document for the chart.]
| Workload (from our ranking) | Market | Latest size | Forecast | Growth a year |
|---|---|---|---|---|
| 1. Clinical development | CRO / clinical trial services | $57.5 to 59.6B (2025) | about $106B (2033 to 2035) | 6.5 to 7.5% |
| 1. Clinical development | eClinical software (EDC, CTMS) | $11.4 to 11.5B | $25.9 to 35.1B (2033 to 2034) | 8 to 15% |
| 2. Regulatory submissions | Regulatory affairs outsourcing | $7.5B (2024) to $8.9B (2025) | $15.7 to 16.2B (2034) | 7 to 7.6% |
| 2. Regulatory submissions | Medical writing | $5.1B (2025) | $10.3 to 11.1B (2032 to 2033) | about 10% |
| 3. Pharmacovigilance | PV services and software | $8.6 to 11.8B (2025) | $13.5 to 24.8B (2030 to 2034) | 5.6 to 15.9% |
| 4. Quality and GMP | Life sciences QMS software | $3.7 to 3.9B (2025) | $10.1 to 11.4B (2033 to 2034) | 12.8 to 13.8% |
| Cross-cutting | AI in drug discovery | $2.3 to 6.9B (2025) | $13.8 to 16.5B (2033 to 2034) | 10 to 25% |
Adding the low and high ends of the services and software markets gives roughly $95 to $110 billion a year (our arithmetic; markets may overlap). Clinical trial services alone are about 55 to 60% of that. The fastest growth is in software and AI, not in services.
Clinical development: CROs and eClinical software
CROs are the biggest single market.
- Grand View Research puts the healthcare contract research market at $59.6 billion in 2025, growing 7.5% a year to $105.7 billion by 2033. North America holds 40.2% and clinical work 75.4%, and oncology is the largest therapy area (30.8%).
- Global Market Insights’ estimate is similar: $57.5 billion, reaching $107.6 billion by 2035.
- Research firms cite rising trial complexity and outsourcing by drug developers as growth drivers. That matches the protocol data in our workload article.
Company revenue as a reality check (2025):
| Company | Revenue | Backlog |
|---|---|---|
| IQVIA, R&D Solutions segment | $8.9 billion | $32.7 billion |
| ICON | $8.3 billion (+0.8%) | $21.8 billion |
| Medpace | $2.5 billion (+20%) | $3.0 billion |
IQVIA and ICON alone account for about $17 billion, close to 30% of the market estimates.
eClinical software (electronic data capture, trial management) is about $11.4 to 11.5 billion. Grand View forecasts 15% growth a year to 2033, and Precedence 8%. One major listed supplier reported $3.2 billion of total revenue in its fiscal year to January 2026, up 16%.
Regulatory, safety, quality, and AI
Regulatory affairs outsourcing.
- IMARC: $8.9 billion in 2025, reaching $16.2 billion by 2034 (6.9% a year).
- Global Market Insights: $7.5 billion in 2024, reaching $15.7 billion by 2034 (7.6% a year).
Medical writing. Grand View and Coherent both put it at about $5.1 billion in 2025, growing about 10% a year. Medical writing is the main workload for clinical study reports and submission documents. One firm’s page shows a figure around 35 times higher, which looks like an error, and we have not used it.
Pharmacovigilance. Estimates range from $8.6 billion (Grand View) to $11.8 billion (ResearchAndMarkets) in 2025. Forecast growth ranges from 5.6% to 15.9% a year, depending on whether the estimate covers outsourced services, software, or both. With FDA receiving about 2.2 million electronic adverse event submissions a year, case processing is the main cost: Deloitte (2019) found it takes 40 to 85% of pharmacovigilance budgets.
Quality management software (QMS).
- Grand View: $3.7 billion in 2025 for life sciences QMS software, growing 13.8% a year to $10.1 billion by 2033.
- Straits: $3.87 billion, reaching $11.4 billion by 2034.
AI. This is the smallest market today, but the fastest growing.
| Market | 2025 size | Forecast | Growth a year | Source |
|---|---|---|---|---|
| AI in drug discovery | $2.3B | $13.8B (2033) | 24.8% | Grand View |
| AI in drug discovery | $6.9B | $16.5B (2034) | 10.1% | Precedence |
| AI in life sciences | $2.7B | $15.9B (2035) | 19.3% | Precedence |
| Generative AI in life sciences | $0.3B | $1.7B (2034) | 20.8% | Towards Healthcare / Precedence |
McKinsey estimates generative AI’s potential value in pharma at $60 to 110 billion a year. That is many times today’s AI market, which suggests large room for growth.
Why estimates differ
- Scope. “Pharmacovigilance” may mean outsourced services, software, or both. “AI in drug discovery” may or may not include clinical development.
- Base year. Some firms report 2024 and others 2025.
- Errors. One medical writing estimate was about 35 times higher than the others. Always compare at least two sources.
- Paid releases. Many figures come from press releases distributed by the research firms themselves. Company revenue is the best check.
Using market data in AI and RAG
- Store each estimate with its firm, scope, base year, and release date.
- Show ranges where firms differ.
- Anchor to company filings (IQVIA, ICON, Medpace and listed software suppliers) for verifiable figures.
- Map each market to the workload it serves, as in the overview table.
Common mistakes
- Quoting a single firm’s figure as “the” market size.
- Adding overlapping markets, such as eClinical software and CRO services, without noting the overlap.
- Comparing forecasts that end in different years.
- Using outlier figures without checking them.
Checklist
- Two or more sources per market
- Scope and base year recorded
- Company revenue used as a check
- Outliers flagged
How AskDona helps
AskDona sits where these markets overlap: the documents behind clinical, regulatory, safety, and quality work. Whether that work is done in-house or by a CRO or other vendor, AskDona checks it against the rules and source documents and cites the passage behind each finding.
Run a sample vendor deliverable evidence check
AskDona shows the evidence; your teams decide.
Editor’s note. This article is general information, not investment advice. Market sizes are commercial research estimates with different scopes; we show ranges and name each firm. Company figures come from 2025 annual results. Totals across markets are our arithmetic and may double-count.
FAQ
How big is the CRO market? About $57.5 to 59.6 billion in 2025, growing 6.5 to 7.5% a year.
How big is the pharmacovigilance market? About $8.6 to 11.8 billion in 2025, depending on scope.
What is the fastest-growing segment? AI and software. Life sciences QMS software is growing about 13 to 14% a year, and AI in drug discovery 10 to 25%.
Who are the largest CROs? IQVIA (R&D Solutions, $8.9 billion in 2025 revenue) and ICON ($8.3 billion).
References
All pages opened and checked by October 31, 2026.